Skip to content

SEDVasc (RaDiCo Cohort) (RaDiCo-SEDVasc)

National Cohort on the Vascular Ehlers-Danlos Syndrome (SEDv)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05976841
Enrollment
340
Registered
2023-08-04
Start date
2016-12-05
Completion date
2028-01-01
Last updated
2026-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ehlers-Danlos Syndrome, Vascular Type

Brief summary

The goal of this observational study is to describe the natural course of vascular Ehlers-Danlos syndrome, in particular the order of appearance of different types of complications (arterial, digestive, pulmonary and uterine).

Interventions

None listed

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Patients eligible for inclusion in this study have to fulfil all of the following criteria: * Patients (adults and children) with genetically-proven vEDS (presence of a pathogenic mutation at the COL3A1 gene); * Patients (or his/her legal guardian) who does not oppose to his/her personal data collection. There are no

Exclusion criteria

for this study.

Design outcomes

Primary

MeasureTime frame
Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on the presence of complications at delivery or after C-sectionThrough study completion, an average of 3 years
Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on anatomical criteria (number and type of arterial lesions or angioscanner or MRI)Through study completion, an average of 3 years
Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on functional criteria (spontaneous arterial, digestive, obstetrical and pulmonary events)Through study completion, an average of 3 years
Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on surgical criteria (types and complications)Through study completion, an average of 3 years
Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on evaluation of the quality of life (impact on daily life, social life and professional activity)Through study completion, an average of 3 years
Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on evaluation of mortality (death, disability)Through study completion, an average of 3 years

Secondary

MeasureTime frameDescription
Study of prospective genotype-phenotype relationshipsThrough study completion, an average of 3 yearsMutations of the COL3A1 gene are stratified within 5 classes (Frank et al. Eur J Hum Genet 2015): 1. Glycine substitutions, 2. splice-site and in-frame insertions-deletions, 3. variants leading to haplo-insufficiency, 4. non-glycine missense variants within the triple helix, 5. non-glycine missense variants or in-frame insertions-deletions, in the N- or C-terminal part of the protein An association study between the type of mutation in the COL3A1 gene (individually or combined in two groups: (a+b) versus (c+d+e)) and the clinical phenotype or co-factors of morbidity (medication, lifestyle, smoking, physical activity…) will be performed. This study will be based on explicative multivariate analysis (e.g.: PCA, Logistic regression, ect.) and relevant association will be quantified by the corresponding correlation coefficient.
Study of the intrafamilial phenotypes relationshipsThrough study completion, an average of 3 yearsThis study will be based on an explicative multivariate analysis (eg: PCA, Logistic regression, ect.) and relevant associations will be quantified by the corresponding correlation coefficients. Distribution of clinical symptoms with a positive correlation with the family history, will be displayed and illustrated by appropriate graphic method (Bar chart, box plot, forest plot, etc.).
Evaluation of the global cost of vEDS caresThrough study completion, an average of 3 yearsThe analysis of the global cost of vEDS cares will be detailed by type of expenditure. The average cost will be estimated with health-care payer's perspective, i.e. the French health insurance system. After estimating the average global cost of vEDS cares, including both standard pathway's cost and vEDS' cost, a Tornado diagram will analyse the impact of the change of one or more parameters used in the analysis process. This will allow us to identify which parameters have an impact on the result by introducing uncertainties on values used. These parameters will vary in a range obtained by literature review, expert opinion or arbitrarily by simulation on a normal distribution. All the results will be drafted in statistical medico-economic analysis report to be presented to all investigators at the end of the study.
Evaluation of the therapeutic managementThrough study completion, an average of 3 yearsA descriptive analysis of the different types of medication (celiprolol alone or associated to another drug) and their association to disease progression and life style will be performed by evaluating the number of lesions and/or the increased severity of the lesions and/or the appearance of lesions at different anatomical site.
Assessment of the correlation between the diffusion of arterial lesions and the occurrence of cardiovascular complicationThrough study completion, an average of 3 years
Assessment of the repercussions of vEDS on patients' quality of life evaluated through scores of quality of life questionnaire Short-Form Health Survey (SF-36)Through study completion, an average of 3 years
Assessment of the repercussions of vEDS on patients' quality of life evaluated through scores of quality of life questionnaire Short-Form Health Survey (SF-10)Through study completion, an average of 3 years
Assessment of the repercussions of vEDS on patients' quality of life evaluated through scores of quality of life questionnaire HADSThrough study completion, an average of 3 years
Assessment of the repercussions of vEDS on patients' quality of life evaluated through scores of quality of life questionnaire socio-professional lifeThrough study completion, an average of 3 years

Countries

France

Contacts

PRINCIPAL_INVESTIGATORXavier JEUNEMAITRE

INSERM UMR S970

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026